Nautilus Biotechnology (NAUT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	28.65 mm	28.65 mm	28.65 mm	28.65 mm	28.65 mm	28.65 mm
Cash burn (monthly)	(no burn)	(no burn)	6.66 mm	6.79 mm	4.77 mm	4.93 mm
Cash used (since last report)	n/a	n/a	13.75 mm	14.01 mm	9.85 mm	10.17 mm
Cash remaining	n/a	n/a	14.90 mm	14.63 mm	18.80 mm	18.47 mm
Runway (months of cash)	n/a	n/a	2.2	2.2	3.9	3.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

NAUT institutional ownership history Ownership history

73.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	86	80	+7.5%
Opened positions	9	10	-10.0%
Closed positions	3	4	-25.0%
Increased positions	23	22	+4.5%
Reduced positions	12	20	-40.0%

13F shares	Current	Prev Q	Change
Total value	164.51 bn	134.78 bn	+22.1%
Total shares	91.81 mm	91.62 mm	+0.2%
Total puts	100.00	500.00	-80.0%
Total calls	1.90 k	2.90 k	-34.5%
Total put/call ratio	0.1	0.2	-69.5%

Largest owners	Shares	Value	Change
Capital Management, L.L.C. AH	17.65 mm	$50.31 bn	0.0%
AH Bio Fund II	16.30 mm	$0.00	0.0%
Perceptive Advisors	12.59 mm	$35.89 bn	0.0%
VCVC V	7.17 mm	$37.16 mm	0.0%
Cercano Management	7.17 mm	$20.44 bn	0.0%
Madrona Venture	6.02 mm	$17.16 mm	0.0%
Sciences Holdings ARYA III	4.15 mm	$0.00	0.0%
BlackRock	3.57 mm	$10.16 bn	NEW
Vanguard	2.77 mm	$7.88 bn	+1.6%
Comprehensive Financial Management	2.21 mm	$6.29 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-3.83 mm	EXIT
BlackRock	3.57 mm	+3.57 mm	NEW
Dimensional Fund Advisors	691.99 k	+117.14 k	+20.4%
GS The Goldman Sachs Group, Inc.	162.33 k	+79.44 k	+95.8%
MS Morgan Stanley	400.49 k	+78.93 k	+24.5%
BCS Barclays	106.17 k	+47.06 k	+79.6%
Vanguard	2.77 mm	+42.75 k	+1.6%
BK The Bank of New York Mellon Corporation	106.70 k	-36.64 k	-25.6%
MetLife Investment Management	30.61 k	+30.61 k	NEW
Jane Street	37.68 k	-25.02 k	-39.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NAUT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Sep 24	Mary E. Godwin	Common Stock	Sell	Dispose S	No	No	2.865	47,031	134.74 k	0
23 Sep 24	Mary E. Godwin	Common Stock	Option exercise	Acquire M	No	No	0.46	47,031	21.63 k	47,031
23 Sep 24	Mary E. Godwin	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.46	47,031	21.63 k	353,337
17 Sep 24	Mary E. Godwin	Common Stock	Sell	Dispose S	No	No	2.8534	35,000	99.87 k	0
17 Sep 24	Mary E. Godwin	Common Stock	Option exercise	Acquire M	No	No	0.46	35,000	16.10 k	35,000
17 Sep 24	Mary E. Godwin	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.46	35,000	16.10 k	400,368
16 Sep 24	Kentaro Suzuki	Stock Option Common Stock	Grant	Acquire A	No	No	2.96	375,000	1.11 mm	375,000
14 Jun 24	Posard Matthew L.	Stock Option Common Stock	Grant	Acquire A	No	No	2.56	45,000	115.20 k	45,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Nautilus Biotechnology Q4 GAAP EPS $(0.14) Beats $(0.16) Estimate

27 Feb 25

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is unchanged from the same period last year.

Earnings Scheduled For February 27, 2025

27 Feb 25

Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

5 Dec 24

Goldman Sachs analyst Matthew Sykes downgrades Nautilus Biotechnology (NASDAQ:NAUT) from Neutral to Sell and lowers the price target from $2.25 to $1.75.